Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | NDUFS8 | O00217 | 1/20 | 0.43 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.43 |
| ▸ | NDUFAB1 | O14561 | 1/20 | 0.43 |
| ▸ | NDUFA1 | O15239 | 1/20 | 0.43 |
| ▸ | NDUFS4 | O43181 | 1/20 | 0.43 |
| ▸ | NDUFB5 | O43674 | 1/20 | 0.43 |
| ▸ | NDUFB3 | O43676 | 1/20 | 0.43 |
| ▸ | NDUFC1 | O43677 | 1/20 | 0.43 |
| ▸ | NDUFA2 | O43678 | 1/20 | 0.43 |
| ▸ | NDUFS5 | O43920 | 1/20 | 0.43 |
| ▸ | NDUFS7 | O75251 | 1/20 | 0.43 |
| ▸ | NDUFS2 | O75306 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21314041 | 0.88 | CA1 (0.52) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL13613012 | 0.86 | CA1 (0.53) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL19607565 | 0.86 | NDUFS8 (0.58) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL27741033 | 0.84 | ACACB (0.59) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL23870163 | 0.83 | CA1 (0.45) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL1541945 | 0.83 | CA1 (0.64) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL8757517 | 0.82 | CA2 (0.53) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL19003451 | 0.82 | ACACB (0.61) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL26964370 | 0.82 | CA1 (0.56) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL2187363 | 0.82 | CA1 (0.50) | CA2CA1CA12CA9NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042843-A1 | HIGH DENSITY PEPTIDE POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-02-15 | — | — | US | disclosed |
| US-20170327633-A1 | COMPOSITIONS AND METHODS OF MAKING POLYMERIZING NUCLEIC ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-11-16 | — | — | US | disclosed |
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | CA2 65/4885CA1 1532/4885CA12 626/4885 |
| US-20180042843-A1 | HIGH DENSITY PEPTIDE POLYMERS | ERMP1, PARL, PRAP1 | CA2 4377/4885CA1 2979/4885CA12 3177/4885 |
| US-20170327633-A1 | COMPOSITIONS AND METHODS OF MAKING POLYMERIZING NUCLEIC ACIDS | RNGTT, NSUN2, POLN | CA2 2255/4885CA1 1847/4885CA12 1376/4885 |
| US-20070265303-A1 | Amine derivatives | HNMT, HRH4, CMA1 | CA2 2884/4885CA1 3258/4885CA12 2512/4885 |
| US-20090253739-A1 | Amine Derivatives | HNMT, HRH4, CMA1 | CA2 2884/4885CA1 3258/4885CA12 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.